Which new drugs can enter the "blockbuster" club in the first year of listing (the first 12 natural months)?Hepatitis C drugs marketed in recent years are undoubtedly the "double champion" of medicine and commerce.
An industry observation article published recently by Nature Review Drug Discovery shows that Harvoni and Sovaldi were both selected and ranked first and second in the list for the first year of the new drug market. In addition, Epclusa and Incivek, two hepatitis C drugs, entered the list.
The Sovaldi launched by Gilead in 2013 became the "headline" of media coverage because of its high pricing, and the subsequent launch of the second compound Harvoni set a record for the launch of new drugs, with sales exceeding US $10 billion in the first four quarters of the US market.
Outside of the antiviral field, multiple sclerosis (MS) is another area that is prone to the birth of "blockbusters", such as Baijian's recently marketed oral drug Tecfidera and Roche's CD20 monoclonal antibody Ocrevus.
Lipitor, a statin marketed in 1997, was the first product sold for $1 billion in the 12 months prior to its launch.Although it lost patent protection in 2011, it had sales of $162 billion as of 2017.
Another old product is Celebrex, the COX2 inhibitor of Pfizer (Pharmacia), and in addition the COX2 inhibitor that was withdrawn due to safety concerns Vioxx also entered the top ten.
The following is the list of the best 16 drugs sold in the 12 months before the launch of the new drug.
The best 16 drugs (unit: $100 million) sold in the 12 months prior to marketing
Remarks: Data for this analysis are from EvaluatePharma, excluding combinations of generic drugs, existing products, and vaccines.Unadjusted data are indicated in parentheses and are based on inflation-adjusted data.
References: The industry's biggest drug clouches